MXCT

Company Overview — What Does MAXCYTE, INC. Do?

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. MAXCYTE, INC. (MXCT) is classified as a micro-cap stock in the Industrials sector, specifically within the Business Services industry. The company is led by CEO Douglas A. Doerfler and employs approximately 80 people. With a market capitalization of $80M, MXCT is one of the notable companies in the Industrials sector.

MAXCYTE, INC. (MXCT) Stock Rating — Avoid (April 2026)

As of April 2026, MAXCYTE, INC. receives a Avoid rating with a composite score of 25.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.MXCT ranks #3,926 out of 4,446 stocks in our coverage universe. Within the Industrials sector, MAXCYTE, INC. ranks #673 of 752 stocks, placing it in the lower half of its Industrials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MXCT Stock Price and 52-Week Range

MAXCYTE, INC. (MXCT) currently trades at $0.76. The 52-week high for MXCT is $3.24, which means the stock is currently trading -76.5% from its annual peak. The 52-week low is $0.64, putting the stock 18.1% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is MXCT Overvalued or Undervalued? — Valuation Analysis

MAXCYTE, INC. (MXCT) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.44x, versus the sector average of 2.23x. The price-to-sales ratio is 2.24x, compared to 0.50x for the average Industrials stock.

At current multiples, MAXCYTE, INC. trades at a premium to most Industrials peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

MAXCYTE, INC. Profitability — ROE, Margins, and Quality Score

MAXCYTE, INC. (MXCT) earns a quality factor score of 31/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -27.2%, compared to the Industrials sector average of 8.9%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -23.0% versus the sector average of 3.3%.

On a margin basis, MAXCYTE, INC. reports gross margins of 80.2%, compared to 35.8% for the sector. The operating margin is -166.2% (sector: 6.2%). Net profit margin stands at -141.8%, versus 3.9% for the average Industrials stock. Revenue growth is running at -34.5% on a trailing basis, compared to 6.4% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MXCT Debt, Balance Sheet, and Financial Health

MAXCYTE, INC. has a debt-to-equity ratio of 18.0%, compared to the Industrials sector average of 70.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.30x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $13M.

MXCT has a beta of 1.24, meaning it is more volatile than the broader market — a $10,000 investment in MXCT would be expected to move 24.2% more than the S&P 500 on any given day. The stability factor score for MAXCYTE, INC. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

MAXCYTE, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, MAXCYTE, INC. reported revenue of $34M and earnings per share (EPS) of $-0.42. Net income for the quarter was $-47M. Gross margin was 80.2%. Operating income came in at $-55M.

In FY 2025, MAXCYTE, INC. reported revenue of $33M and earnings per share (EPS) of $-0.42. Net income for the quarter was $-45M. Gross margin was 81.2%. Revenue grew -14.5% year-over-year compared to FY 2024. Operating income came in at $-52M.

In Q3 2025, MAXCYTE, INC. reported revenue of $7M and earnings per share (EPS) of $-0.12. Net income for the quarter was $-12M. Gross margin was 76.6%. Revenue grew -16.4% year-over-year compared to Q3 2024. Operating income came in at $-14M.

In Q2 2025, MAXCYTE, INC. reported revenue of $9M and earnings per share (EPS) of $-0.12. Net income for the quarter was $-12M. Gross margin was 82.1%. Revenue grew -18.4% year-over-year compared to Q2 2024. Operating income came in at $-14M.

Over the past 8 quarters, MAXCYTE, INC. has demonstrated a growth trajectory, with revenue expanding from $10M to $34M. Investors analyzing MXCT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MXCT Dividend Yield and Income Analysis

MAXCYTE, INC. (MXCT) does not currently pay a dividend. This is common among smaller companies in the Business Services industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Industrials dividend stocks may want to explore other Industrials stocks or use the stock screener to filter by dividend yield.

MXCT Momentum and Technical Analysis Profile

MAXCYTE, INC. (MXCT) has a momentum factor score of 10/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

MXCT vs Competitors — Industrials Sector Ranking and Peer Comparison

Within the Industrials sector, MAXCYTE, INC. (MXCT) ranks #673 out of 752 stocks based on the Blank Capital composite score. This places MXCT in the lower half of all Industrials stocks in our coverage universe. Key competitors and sector peers include South Bow Corp (SOBO) with a score of 56.5/100, TSAKOS ENERGY NAVIGATION LTD (TEN) with a score of 61.4/100, Great Lakes Dredge & Dock CORP (GLDD) with a score of 56.7/100, Tri Pointe Homes, Inc. (TPH) with a score of 57.3/100, and Clear Channel Outdoor Holdings, Inc. (CCO) with a score of 52.2/100.

Comparing MXCT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MXCT vs S&P 500 (SPY) comparison to assess how MAXCYTE, INC. stacks up against the broader market across all factor dimensions.

MXCT Next Earnings Date

No upcoming earnings date has been announced for MAXCYTE, INC. (MXCT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MXCT? — Investment Thesis Summary

The quantitative profile for MAXCYTE, INC. suggests caution. The quality score of 31/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Momentum is weak at 10/100, a headwind for near-term performance. High volatility (stability score 31/100) increases portfolio risk.

In summary, MAXCYTE, INC. (MXCT) earns a Avoid rating with a composite score of 25.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MXCT stock.

Related Resources for MXCT Investors

Explore more research and tools: MXCT vs S&P 500 comparison, top Industrials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MXCT head-to-head with peers: MXCT vs SOBO, MXCT vs TEN, MXCT vs GLDD.